1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Cytoskeleton
  3. Kinesin

Kinesin

Kinesins are a family of molecular motors that use the energy of ATP hydrolysis to move along the surface of, or destabilize, microtubule filaments. The kinesin motor protein family consists of 14 distinct subclasses and 45 kinesin proteins in humans. A large number of these proteins, or their orthologues, have been shown to possess essential function(s) in both the mitotic and the meiotic cell cycle. Kinesins also can be classified into three groups based on the position of their motor domains: N-terminal, C-terminal and internal kinesins. Conventional kinesin operates as a dimer, walking in a co-ordinated, hand-over-hand fashion along a microtubule protofilament.

Kinesins have important roles in chromosome separation, microtubule dynamics, spindle formation, cytokinesis and cell cycle progression. Roles of kinesins in diseases typically involve defective transport of cell components, transport of pathogens, or cell division.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-112777
    Kinesore
    Modulator ≥98.0%
    Kinesore is an inhibitor of the KLC2-SKIP Interaction.
    Kinesore
  • HY-122247
    PVZB1194
    Inhibitor 99.90%
    PVZB1194 is a biphenyl-type inhibitor of Kinesin-5 ATPase activity that binds to the α4/α6 site of the motor domain in a nucleotide competitive manner. PVZB1194 has an IC50 of 0.12 μM for KSP ATPase. PVZB1194 induces mitotic arrest with the formation of a monopolar spindle, and inhibits HeLa cells proliferatio (IC50: 5.5 μM). PVZB1194 can be used in the study of tumors.
    PVZB1194
  • HY-19530
    PF-2771
    Inhibitor 99.66%
    PF-2771 is a potent and selective centromere protein E (CENP-E) inhibitor, inhibiting CENP-E motor activity with an IC50 of 16.1 nM; PF-2771 is used as an anticancer agent.
    PF-2771
  • HY-145034
    KIF18A-IN-1
    Inhibitor 98.39%
    KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity.
    KIF18A-IN-1
  • HY-13224
    AZD4877
    Inhibitor 99.49%
    AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC50 of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity.
    AZD4877
  • HY-115570
    GW406108X
    Inhibitor ≥98.0%
    GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC50 of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK.
    GW406108X
  • HY-50672
    MK-0731
    Inhibitor 99.85%
    MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6. MK-0731 is >20,000 fold selectivity against other kinesins. MK-0731 induces mitotic arrest and induces apoptosis in tumors. MK-0731 provides significant antitumor efficacy.
    MK-0731
  • HY-153066
    VLS-1272
    Inhibitor 98.09%
    VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CINHigh tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research.
    VLS-1272
  • HY-16062
    ARQ 621
    Inhibitor ≥99.0%
    ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity. ARQ 621 is a kinesin inhibitor. ARQ 621 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ARQ 621
  • HY-19966
    K858 (Racemic)
    Inhibitor 99.83%
    K858 Racemic is an ATP-uncompetitive inhibitor of kinesin Eg5 with an IC50 of 1.3 μM.
    K858 (Racemic)
  • HY-110208
    BRD9876
    98.82%
    BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research.
    BRD9876
  • HY-160441
    MC-Val-Cit-PAB-Ispinesib
    Inhibitor 99.85%
    MC-Val-Cit-PAB-Ispinesib (Compound 509) is a potent inhibitor of Eg5. MC-Val-Cit-PAB-Ispinesib is a click chemistry reagent.
    MC-Val-Cit-PAB-Ispinesib
  • HY-145803
    KIF18A-IN-3
    Inhibitor 99.30%
    KIF18A-IN-3 is a potent KIF18A inhibitor (IC50=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer.
    KIF18A-IN-3
  • HY-15949
    Kif15-IN-2
    Inhibitor 98.64%
    Kif15-IN-2 is an inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases.
    Kif15-IN-2
  • HY-162110
    AM-9022
    Inhibitor 99.48%
    AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer.
    AM-9022
  • HY-15187A
    (R)-Filanesib
    Inhibitor 98.80%
    (R)-Filanesib ((R)-ARRY-520) is the R-enantiomer of Filanesib (HY-15187). Filanesib is a synthetic kinesin spindle protein (KSP) inhibitor with an IC50 of 6 nM.
    (R)-Filanesib
  • HY-112915
    Eg5 Inhibitor V, trans-24
    Inhibitor 98.18%
    Eg5 Inhibitor V, trans-24 is a potent and specific kinesin Eg5 inhibitor with an IC50 of 0.65 μM, and can be used in the research of cancer.
    Eg5 Inhibitor V, trans-24
  • HY-145802
    KIF18A-IN-2
    Inhibitor 99.34%
    KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer.
    KIF18A-IN-2
  • HY-121569
    Syntelin
    Inhibitor 98.25%
    Syntelin is a selective centromere protein E (CENP-E) inhibitor with IC50 at 160 nM. Syntelin has antitumor activity.
    Syntelin
  • HY-14846A
    Litronesib Racemate
    99.20%
    Litronesib Racemate (LY2523355 Racemate) is the racemate of litronesib. Litronesib is a selective, allosteric inhibitor of kinesin Eg5.
    Litronesib Racemate
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.